BeLiver emerged from the pioneering work of Bordeaux University Hospital (CHU) and the INSERM/CNRS research unit BRIC (Bordeaux Institute Of Oncology).

Our founders identified a critical gap : patients with the same diagnosis often respond very differently to standard treatments. The reason? A lack of tools to truly capture the biological complexity of each tumor.

This challenge became our mission : to develop a new generation of decision-support tools that bring rationality and clarity to therapeutic choices.

By combining advanced proteomics with AI, we deliver personalized treatment predictions ensuring each patient receives the right therapy from day one.